Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer

Optimal therapy for clinically node-positive, nonmetastatic (cN1) prostate cancer (PC) patients remains controversial, ranging from aggressive local therapy to palliative systematic therapy alone. Despite guideline support, it is unclear if a brachytherapy (BT) boost should be considered for cN1 patients as these patients were excluded from randomized trials establishing its benefit. Herein, we compare definitive radiation therapy (RT) with or without a BT boost in cN1 PC.

Source: Brachytherapy - July 2, 2020 Category: Cancer & Oncology Authors: Benjamin W. Fischer-Valuck, Yuan James Rao, Randall J. Brenneman, Pretesh R. Patel, Christopher P. Filson, Ashesh B. Jani, Yuan Liu, Subir Goyal, Karen Xu, Aaron Weiss, Omer Kucuk, Cara Cimmino, Stephen Szabo, Peter Rossi, Brian C. Baumann, John Pattaras, Source Type: research